GRM1
Metabotropic glutamate receptor 1
Also known as: GPRC1A, GRM1_HUMAN, mGlu1, MGLUR1, PPP1R85
Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene
Protein identityUniProt · HPA
- UniProt accession
- Q13255
- Gene
- GRM1
- Ensembl
- ENSG00000152822
- Chromosome
- 6
- Canonical length
- 1194 aa
- Protein class
- Disease related genes, G-protein coupled receptors, Human disease related genes, Plasma proteins, Potential drug targets, Predicted membrane proteins, Transporters
- Subcellular location
- Vesicles
- Quaternary structure
- Homodimer
OverviewNCBI Gene
This gene encodes a metabotropic glutamate receptor that functions by activating phospholipase C. L-glutamate is the major excitatory neurotransmitter in the central nervous system and activates both ionotropic and metabotropic glutamate receptors. Glutamatergic neurotransmission is involved in most aspects of normal brain function and can be perturbed in many neuropathologic conditions. The canonical alpha isoform of the encoded protein is a disulfide-linked homodimer whose activity is mediated by a G-protein-coupled phosphatidylinositol-calcium second messenger system. This gene may be associated with many disease states, including schizophrenia, bipolar disorder, depression, and breast cancer. Alternative splicing results in multiple transcript variants encoding different isoforms. [provided by RefSeq, May 2013]
Canonical amino-acid sequenceUniProt
1194 residues, UniProt reviewed canonical sequence.
>Q13255|GRM1
1 MVGLLLFFFP AIFLEVSLLP RSPGRKVLLA GASSQRSVAR MDGDVIIGAL FSVHHQPPAE
61 KVPERKCGEI REQYGIQRVE AMFHTLDKIN ADPVLLPNIT LGSEIRDSCW HSSVALEQSI
121 EFIRDSLISI RDEKDGINRC LPDGQSLPPG RTKKPIAGVI GPGSSSVAIQ VQNLLQLFDI
181 PQIAYSATSI DLSDKTLYKY FLRVVPSDTL QARAMLDIVK RYNWTYVSAV HTEGNYGESG
241 MDAFKELAAQ EGLCIAHSDK IYSNAGEKSF DRLLRKLRER LPKARVVVCF CEGMTVRGLL
301 SAMRRLGVVG EFSLIGSDGW ADRDEVIEGY EVEANGGITI KLQSPEVRSF DDYFLKLRLD
361 TNTRNPWFPE FWQHRFQCRL PGHLLENPNF KRICTGNESL EENYVQDSKM GFVINAIYAM
421 AHGLQNMHHA LCPGHVGLCD AMKPIDGSKL LDFLIKSSFI GVSGEEVWFD EKGDAPGRYD
481 IMNLQYTEAN RYDYVHVGTW HEGVLNIDDY KIQMNKSGVV RSVCSEPCLK GQIKVIRKGE
541 VSCCWICTAC KENEYVQDEF TCKACDLGWW PNADLTGCEP IPVRYLEWSN IESIIAIAFS
601 CLGILVTLFV TLIFVLYRDT PVVKSSSREL CYIILAGIFL GYVCPFTLIA KPTTTSCYLQ
661 RLLVGLSSAM CYSALVTKTN RIARILAGSK KKICTRKPRF MSAWAQVIIA SILISVQLTL
721 VVTLIIMEPP MPILSYPSIK EVYLICNTSN LGVVAPLGYN GLLIMSCTYY AFKTRNVPAN
781 FNEAKYIAFT MYTTCIIWLA FVPIYFGSNY KIITTCFAVS LSVTVALGCM FTPKMYIIIA
841 KPERNVRSAF TTSDVVRMHV GDGKLPCRSN TFLNIFRRKK AGAGNANSNG KSVSWSEPGG
901 GQVPKGQHMW HRLSVHVKTN ETACNQTAVI KPLTKSYQGS GKSLTFSDTS TKTLYNVEEE
961 EDAQPIRFSP PGSPSMVVHR RVPSAATTPP LPSHLTAEET PLFLAEPALP KGLPPPLQQQ
1021 QQPPPQQKSL MDQLQGVVSN FSTAIPDFHA VLAGPGGPGN GLRSLYPPPP PPQHLQMLPL
1081 QLSTFGEELV SPPADDDDDS ERFKLLQEYV YEHEREGNTE EDELEEEEED LQAASKLTPD
1141 DSPALTPPSP FRDSVASGSS VPSSPVSESV LCTPPNVSYA SVILRDYKQS SSTLLocalizationUniProt · AlphaFold · HPA
Whether an antibody against GRM1 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.
- Antibody reachability
- Cell surface
- Secreted
- No
- Transmembrane segments
- 7
- Mean surface accessibility (rSASA)
- 0.41
- Highest tissue expression
- 16 nTPM
Expression across tissuesHPA
Tissue
- cerebellum: 16 nTPM
- retina: 5.1 nTPM
- cerebral cortex: 4 nTPM
- heart muscle: 2.6 nTPM
- hippocampal formation: 2.6 nTPM
- hypothalamus: 1.8 nTPM
Single-cell type
- brain excitatory neurons: 529 nCPM
- rod photoreceptor cells: 393 nCPM
- brain inhibitory neurons: 329 nCPM
- retinal ganglion cells: 131 nCPM
- other brain neurons: 99 nCPM
- retinal amacrine cells: 85 nCPM
Immune cell
- NK-cell: 0.1 nTPM
- basophil: 0 nTPM
- classical monocyte: 0 nTPM
- eosinophil: 0 nTPM
- gdT-cell: 0 nTPM
- intermediate monocyte: 0 nTPM
Brain region
- cerebellum: 75 nTPM
- hippocampal formation: 32 nTPM
- thalamus: 32 nTPM
- cerebral cortex: 31 nTPM
- basal ganglia: 22 nTPM
- amygdala: 22 nTPM
DiseaseUniProt · ClinVar · IEDB · PubMed
Four sources answering four different questions about GRM1.
Disease | AllUniProt
Conditions GRM1 is implicated in, by any mechanism.
- Spinocerebellar ataxia, autosomal recessive, 13 (SCAR13) MIM:614831
- Spinocerebellar ataxia 44 (SCA44) MIM:617691
Disease | GeneticClinVar
14 pathogenic / likely-pathogenic of 445 ClinVar records.
Conditions with pathogenic or likely-pathogenic variants.
- Autosomal recessive spinocerebellar ataxia 13
- Spinocerebellar ataxia 44
- Global developmental delay
- Cerebellar ataxia
Disease | AutoantibodyPubMed
Conditions in which antibodies against GRM1 are reported. Each links to that disease's full target list.
Showing 4 of 7 — disease pages carrying at least 10 antigens.
ReferencesPubMed · IEDB
Publications for GRM1 from three distinct lines of evidence, kept separate because they answer different questions: whether antibodies are directed at the protein, whether a B-cell epitope has been mapped on it, and whether a T-cell epitope has. Each is labelled with its source.
Reference: AutoantibodyPubMed
21 publications
- Paraneoplastic cerebellar degeneration associated with antineuronal antibodies: analysis of 50 patients.
2003 · Brain · RCR 9.9 · 373 citations - Antibodies to metabotropic glutamate receptor 5 in the Ophelia syndrome.
2011 · Neurology · RCR 6.7 · 230 citations - Autoimmune/Paraneoplastic Encephalitis Antibody Biomarkers: Frequency, Age, and Sex Associations.
2022 · Mayo Clin Proc · RCR 6.3 · 57 citations - Clinical features, prognostic factors, and antibody effects in anti-mGluR1 encephalitis.
2020 · Neurology · RCR 4.5 · 84 citations - Assessing Commercial Tissue-Based Assays for Autoimmune Neurologic Disorders (II): Antibodies to Surface Antigens.
2025 · Neurol Neuroimmunol Neuroinflamm · RCR 3.9 · 10 citations
Show 16 more
- MOG-IgG1 and co-existence of neuronal autoantibodies.
2021 · Mult Scler · RCR 3.4 · 43 citations - Mechanisms underlying cerebellar motor deficits due to mGluR1-autoantibodies.
2003 · Ann Neurol · RCR 3.1 · 149 citations - Anti-mGluR1 encephalitis: Case illustration and systematic review.
2023 · Front Neurol · RCR 2.2 · 16 citations - Canine idiopathic generalized tremor syndrome, immune-mediated?
2024 · Front Vet Sci · RCR 1.6 · 5 citations - Patient with homer-3 antibodies and cerebellitis.
2013 · JAMA Neurol · RCR 1.6 · 50 citations - Cerebellar degeneration associated with mGluR1 autoantibodies as a paraneoplastic manifestation of prostate adenocarcinoma.
2013 · J Neuroimmunol · RCR 1.4 · 42 citations - Long-term clinical follow-up of a patient with non-paraneoplastic cerebellar ataxia associated with anti-mGluR1 autoantibodies.
2018 · J Neuroimmunol · RCR 1 · 21 citations - Autoimmune Encephalitis With mGluR1 Antibodies Presenting With Epilepsy, but Without Cerebellar Signs: A Case Report.
2022 · Neurol Neuroimmunol Neuroinflamm · RCR 1 · 10 citations - Cerebellar ataxia with anti-mGluR1 auto-antibody in a pediatric patient: A case report.
2023 · J Neuroimmunol · RCR 0.9 · 6 citations - Video NeuroImages: Head titubation in anti-mGluR1 autoantibody-associated cerebellitis.
2018 · Neurology · RCR 0.8 · 16 citations - Reversible myoclonus-ataxia encephalitis related to anti-mGLUR1 autoantibodies.
2019 · Mov Disord · RCR 0.6 · 11 citations - Antibodies against metabotropic glutamate receptor type 1 in a toddler with acute cerebellitis.
2020 · J Neuroimmunol · RCR 0.5 · 12 citations - The metabotropic glutamate receptor 1, GRM1: evaluation as a candidate gene for inherited forms of cerebellar ataxia.
2010 · J Neurol · RCR 0.4 · 16 citations - [Novel Autoantibody-Related Encephalitis: anti-mGluR1 encephalitis, anti-IgLON5 disease, autoimmune GFAP astrocytopathy].
2021 · Brain Nerve - Gluten Ataxia and mGluR1 Autoimmune Encephalitis Presenting as Acute Cerebellar Ataxia: A Case Report.
2024 · S D Med - Autoimmune encephalitis with Anti-mGluR1 antibodies: a comprehensive review.
2025 · J Neurol · 1 citations
Sources: PubMed — antigen-level antibody evidence from a custom retrieval. Records matching a controlled set of autoantibody terms (the MeSH descriptors Autoantibodies and Autoantigens, with title and abstract term variants) were obtained through NCBI E-utilities, and their titles and abstracts parsed for constructions that direct an antibody at a named protein rather than for co-occurrence. Captured names were resolved against UniProt nomenclature and each antigen adjudicated individually against the source text. Bibliographic records from PubMed and MeSH, U.S. National Library of Medicine; citation metrics from NIH iCite (Hutchins et al., PLoS Biology 2016). Titles link to PubMed; abstracts are not reproduced here. The NLM does not endorse this analysis.
Genetic constraint and essentialitygnomAD · DepMap
Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.
- gnomAD LOEUF (loss-of-function intolerance)
- 0.42
- gnomAD pLI
- 0.14
- gnomAD missense Z
- 2.58
- DepMap mean gene effect
- 0.12
- DepMap dependency class
- selective
Cancer expressionTCGA
Across TCGA tumor cohorts, this protein is over-expressed in roughly 3% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).
OntologyGO
Biological processes
- cellular response to electrical stimulus
- chemical synaptic transmission
- G protein-coupled glutamate receptor signaling pathway
- G protein-coupled receptor signaling pathway
- L-glutamate import across plasma membrane
- locomotory behavior
- phospholipase C-activating G protein-coupled glutamate receptor signaling pathway
- phospholipase C-activating G protein-coupled receptor signaling pathway
- positive regulation of MAPK cascade
- regulation of sensory perception of pain
- regulation of synaptic transmission, glutamatergic
- sensory perception of pain
- synaptic signaling via neuropeptide
Molecular functions
- adenylate cyclase inhibiting G protein-coupled glutamate receptor activity
- G protein-coupled receptor activity
- G protein-coupled receptor activity involved in regulation of postsynaptic membrane potential
- glutamate receptor activity
- neurotransmitter receptor activity involved in regulation of postsynaptic cytosolic calcium ion concentration
- G protein-coupled neurotransmitter receptor activity involved in regulation of postsynaptic cytosolic calcium ion concentration
Cellular components
- dendriole
- glutamatergic synapse
- nucleus
- plasma membrane
- postsynaptic density membrane
- Schaffer collateral - CA1 synapse
- G protein-coupled receptor dimeric complex
- G protein-coupled receptor homodimeric complex
Protein domainsUniProt · Pfam · InterPro
- GPCR, family 3, metabotropic glutamate receptor
- GPCR, family 3
- Receptor, ligand binding region
- GPCR, family 3, nine cysteines domain
- GPCR family 3, C-terminal
- GPCR, family 3, conserved site
- Metabotropic glutamate receptor, Homer-binding domain
- Periplasmic binding protein-like I
- GPCR, family 3, nine cysteines domain superfamily
- Metabotropic Glutamate Receptor
- 7 transmembrane sweet-taste receptor of 3 GCPR
- Receptor family ligand binding region
- Nine Cysteines Domain of family 3 GPCR
- Homer-binding domain of metabotropic glutamate receptor
- GPCR, family 3, metabotropic glutamate receptor 1
KeywordsUniProt
InteractionsUniProt · HPA
Protein binding partners of GRM1 in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.
Antibody and autoantibody relevanceSeroatlas analysis
Seroatlas reads GRM1 as an antibody target. Whether an autoantibody or antibody against GRM1 could matter depends on whether native GRM1 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.
GRM1 is annotated at the cell surface, where native GRM1 is exposed to circulating antibodies and is a prime autoantibody target that could block, deplete, or overstimulate it.
Annotation status
The present source text does not explicitly label GRM1 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.
Loading the interactive Seroatlas protein explorer...